Nektar Therapeutics (NKTR) Free Cash Flow (2010 - 2026)

Nektar Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$44.3 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 9.66% year-over-year to -$44.3 million; the TTM figure through Mar 2026 stood at -$203.9 million (down 14.45% YoY), while the FY2025 annual figure was -$208.7 million, down 17.78% from the prior year.
• Free Cash Flow was -$44.3 million for Q1 2026 at Nektar Therapeutics, up from -$65.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$37.9 million in Q2 2024 to a low of -$92.6 million in Q1 2022.
• Historically, Free Cash Flow has averaged -$54.9 million across 5 years, with a median of -$48.9 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow soared 63.02% in 2022, then plunged 39.3% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$58.2 million in 2022, then grew by 18.78% to -$47.3 million in 2023, then increased by 1.35% to -$46.6 million in 2024, then slumped by 39.3% to -$65.0 million in 2025, then surged by 31.8% to -$44.3 million in 2026.
• The last three Free Cash Flow figures came in at -$44.3 million (Q1 2026), -$65.0 million (Q4 2025), and -$48.9 million (Q3 2025), per Business Quant data.